#AS­CO19: Clay Sie­gall is ready to take a big leap for­ward as Seat­tle Ge­net­ics’ next top drug prospect steps on­to cen­ter stage at AS­CO

CHICA­GO — Clay Sie­gall is com­ing up to a fin­ish line he’s been walk­ing, run­ning and crawl­ing to­ward — in stages, as re­quired — for the past 21 years, ever since he found­ed Seat­tle Ge­net­ics.

This morn­ing he re­vealed more about the piv­otal-stage an­ti­body drug con­ju­gate he and Aya Jakobovits put to­geth­er when she was CSO at Agen­sys. Now part­nered with Astel­las, which bought out the biotech in 2007 and stepped in­to the shoes of a 50-50 part­ner­ship, his com­pa­ny is steer­ing in­to what could shape up as a quick re­view for a drug bound for pa­tients with no ap­proved op­tions left — with a break­through drug des­ig­na­tion to its cred­it to help keep things on the fast track at an FDA that has be­come ex­pert at this.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER